Shorted
Arovella Therapeutics logo
ALA
Pharmaceuticals, Biotechnology & Life Sciences

Arovella Therapeutics

Short interest
0.00%
0.00 pp 30d
as of 16 June 2026
Reported shorts
1.8K
Shares on issue
1.209B

Arovella Therapeutics (ALA) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
7 Sept

What’s Behind Arovella Therapeutics (ASX:ALA) and Its Cell Therapy Pipeline?

Highlights Arovella Therapeutics (ASX:ALA) is examined through a capacity expansion lens, with its core activity centred on develops cell therapies and related immuno-oncology programmes. The article focuses on company-specific operating mechanics rather than repeating a broad market narrative. Corporate disclosures provide the factual reference points for the business, its resources and its industry setting. Arovella Therapeutics (ASX:ALA) belongs to the Penny Stocks category and operates th...

Continue reading
Kalkine
Neutral
12 Aug

Arovella Therapeutics Updates Investors on iNKT Cell Therapy Platform and ALA-101 Clinical Trial Progress

Arovella Therapeutics (ASX:ALA), a clinical-stage biotech firm developing an "off-the-shelf" invariant Natural Killer T (iNKT) cell therapy platform, held an investor webinar on 12 August 2026 to share updates following the Board of Directors' recent strategic review. Key Highlights Chairman Dr David Williams and Acting CEO Dr Nicole van der Weerden led the webinar on 12 August 2026 at 2:00 PM AEST. Discussion focused on advancing the iNKT cell therapy platform and the imminent clinical devel...

Continue reading
Kalkine
Neutral
11 Aug

Arovella Therapeutics Announces Investor Webinar on iNKT Cell Therapy Progress and ALA-101 Clinical Trial

Arovella Therapeutics (ASX:ALA), a clinical-stage biotech firm developing an "off-the-shelf" invariant Natural Killer T (iNKT) cell therapy platform, will host an investor webinar on 12 August 2026 at 2:00 PM AEST to share updates following the Board of Directors' recent strategic review. Key Highlights Investor webinar set for 12 August 2026 at 2:00 PM AEST, hosted by Bell Potter Presentations by Chairman Dr David Williams and Acting CEO Dr Nicole van der Weerden Discussion on company’s iN...

Continue reading
Kalkine
Positive
29 June

Why Are Investors Watching (ASX:ALA) in the ASX Smallcap Rally?

Highlights Market focus shifts toward clinical and commercial evidence Funding cycles and execution timelines under closer review Smallcap sentiment shaped by broader ASX rotation signals ASX smallcap health-tech attention is being driven by shifting sentiment, funding conditions, and commercial validation signals across the broader equity market landscape. The discussion around health-tech small-cap proof has re-emerged as market participants reassess h...

Continue reading
Kalkine
Neutral
7 May

Arovella Leadership Shift Draws Attention on Clinical Focus

Highlights Leadership transition announced at Arovella Therapeutics Clinical development strategy remains in focus Board signals continuity during transition phase Arovella Therapeutics has announced a leadership transition as the company continues advancing its clinical ambitions and broader biotechnology strategy within the Australian healthcare sector. Australian biotechnology company Arovella Therapeutics (ASX:ALA) has entered a new phase following the appointment of an acting chief...

Continue reading